Skip to main content

This website is intended exclusively for healthcare professionals residing and/or working in the UAE.

  1. Article
  2. Source: Campus Sanofi
  3. 4 Jun 2025

Look beyond the symptoms to identify and manage Patients with Type 2 Inflammation

Author: Sanofi

Editorial Team

   

Identify > Target > Treat

Identify

80% of Patients with CRSwNP Have Type 2 Inflammation1,a

jcr content 5 1

Look for other signs of type 2 inflammation in patients with CRSwNP2,3

History of asthma and/or other Type 2 comorbidities (allergic rhinitis, NSAID-ERD, etc.) 

and/or 

Elevated EOS and/or elevated total IgE levels 

and/or 

Need for systemic corticosteroi

Consider type 2 inflammation as the key underlying cause of CRSwNP4,5

~3x    more revision surgeries in CRSwNP patients with coexisting asthma6

50%    of CRSwNP patients have coexisting asthma7

a In Western countries.

Target

Target key and central drivers of Type 2 Inflammation

IL-4 and IL-13 are key and central drivers of Type 2 inflammation in CRSwNP4,5

3 20 1

Tissue remodeling, polyp formation, and symptoms, including nasal obstruction, nasal discharge, and loss of smell

Target Key and Central Drivers of Type 2 Inflammation

IL-4, IL-13, and IL-5 have distinct and overlapping roles with a broad impact on CRSwNP symptoms4,5

 IL-14IL-3IL-5
Th2 cell differentiation✓  
B-cell class switching and IgE production✓✓ 
Epithelial barrier dysfunction, goblet cell hyperplasia, and mucus hypersecretion✓✓ 
Tissue remodeling and polyp formation✓✓ 
Eosinophilic recruitment and trafficking to nasal mucosa and polyp tissue✓✓✓
Eosinophil differentiation in bone marrow  ✓

Current Standard-of-Care does not specifically target chronic underlying Type 2 Inflammation

Systemic corticosteroids

  • Treat inflammation broadly3
  • Frequent use leads to risk of short-term and long-term adverse effects8

Targeting Type 2 inflammation can help you achieve treatment goals.

Sino-nasal surgery

  • Removes nasal obtrsuction, but does not aedssd r underlying chronic type 2 inflammation, which may lead to polyp recurrence and refractory symptoms2,3
  • Many patients don't ecrover their sense of s m ell after surgery9
  • Revision sugrery is saosciated with an ienacsred risk of surgical complications10,11

Many patients with Type 2 inflammation experienced Polyp recurrence within 5 years of Sino-nasal surgery12

10

Type 2 inflammation is the underlying cause of CRSwNP in 80% of patients1

Treat

Consider a Biologic that targets Type 2 Inflammation in patients with uncontrolled CRSwNP

  • Type 2 inflammation is the underlying cause of CRSwNP in 80% of patients1

  • IL-4 and IL-13 are key and central type 2 cytokines in the pathophysiology of CRSwNP
    • IL-4, IL-13, and IL-5 are key type 2 cytokines4,5
  • CRSwNP and asthma frequently coexist, adding substantially to the overall disease burden and limiting the effectiveness of surgery and systemic steroids1-3,13-16
  • Guidelines recommend use of biologics in CRSwNP patients to address type 2 inflammation2,3

Guidelines

Guidelines Recommend Use of Biologics in CRSwNP Patients to Address Type 2 Inflammation

EPOS and EUFOREA recommend biological treatments for patients with bilateral polyps who have had prior ESS if they meet at least 3 of the 5 following criteria2,3:

  • Evidence of Type 2 Inflammationa
  • Need for systemic corticosteroids or contraindication to systemic steroids
  • Significantly impaired quality of life
  • Significant loss of smell
  • Diagnosis of comorbid asthma

In patients who have had no prior sinus surgery, 4 out of 5 criteria should be fulfilled2

a Tissue EOS ≥10/hpf, OR blood EOS ≥250, OR total IgE ≥100.

MAT-BH-2400173/V1/April2024  

Related

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
SitemapLegal noticePrivacy PolicyCookie PolicyContactAccessibility statement

© Sanofi 2004-2026 - All rights reserved

MAT-AE-2100444/V8/JUL2025

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
SitemapLegal noticePrivacy PolicyCookie PolicyContactAccessibility statement

© Sanofi 2004-2026 - All rights reserved

MAT-AE-2100444/V8/JUL2025